ArticleBriefings in bioinformatics2026
SHEST: single-cell-level artificial intelligence from haematoxylin and eosin morphology for cell-type prediction and spatial transcriptomics reconstruction.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A comprehensive understanding of cancer progression requires integrating tissue morphology with spatial molecular profiles. We present SHEST, a multi-task profiling framework that leverages haematoxylin and eosin morphology to predict cellular composition and reconstruct spatial gene expression at single-cell resolution. SHEST employs a quadruple-tile input capturing nuclear and contextual information, combined with a neighbourhood-informed clustering algorithm to filter ambiguous cellular signals. It comprises a shared morphological encoder with two task-specific heads: a classifier for cell-type prediction and a reconstructor for gene expression. Multi-task optimization uses cross-entropy and zero-inflated negative binomial losses, specifically addressing the sparsity of spatial transcriptomic data. Evaluation on human lung adenocarcinoma datasets demonstrated high accuracy for the principal reciprocal constituents of the tumour-immune axis ($F_{1}$: 0.97 for tumour cells and 0.91 for lymphocytes). External validation confirmed its generalizability, revealing alveolar cells and their early neoplastic transitions. Reconstructed gene expression reproduced spatially resolved, cell-type-specific marker patterns-EPCAM in tumour cells, LTBP2 in fibroblasts, and CD3E in lymphocytes-recovering biologically coherent transcriptional architecture. SHEST also preserved distance-dependent spatial relationships and gene-level autocorrelation, reflecting the multicellular niche structure of the tumour microenvironment. By unifying cell-type identification, gene expression reconstruction, and spatial mapping within a single interpretable framework, SHEST provides a synergistic and cost-efficient bridge between histopathology and spatial transcriptomics. This approach facilitates comprehensive tissue characterization and forms a foundation for precision oncology through spatially informed, cell-level insights into tumour-immune ecosystems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.